Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 12:00 p.m. ET in New York, NY. The presentation will be accessible via live webcast on Milestone's website, with an archived replay available for 90 days. Milestone focuses on innovative cardiovascular medicines, with its lead product candidate etripamil in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation. For more details, visit www.milestonepharma.com.

News Market Reaction – MIST

-2.54%

-2.54% Session move

In the trading session that priced this news, MIST declined 2.54%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MONTREAL and CHARLOTTE, N.C., Sept. 6, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the H.C. Wainwright 24^th Annual Global Investment Conference on Monday, September 12, 2022 at 12:00 p.m. ET in New York, NY.

A live webcast of the presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301617233.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

When will Milestone Pharmaceuticals present at the H.C. Wainwright conference?

Milestone Pharmaceuticals will present on September 12, 2022, at 12:00 p.m. ET.

Who is presenting for Milestone Pharmaceuticals at the conference?

Joseph Oliveto, the CEO of Milestone Pharmaceuticals, will be presenting.

How can I access Milestone Pharmaceuticals' conference presentation?

The presentation will be available via live webcast on Milestone's website and will have an archived replay for 90 days.

What is the focus of Milestone Pharmaceuticals?

Milestone Pharmaceuticals focuses on developing and commercializing innovative cardiovascular medicines.

What is Milestone Pharmaceuticals' lead product candidate?

Milestone's lead product candidate is etripamil, currently in Phase 3 trials for paroxysmal supraventricular tachycardia.